

# Agnes S M Yong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2132324/publications.pdf>

Version: 2024-02-01

67  
papers

3,959  
citations

126708

33  
h-index

123241

61  
g-index

68  
all docs

68  
docs citations

68  
times ranked

4558  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. <i>Blood</i> , 2021, 137, 1196-1207.	0.6	48
2	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6436.	5.8	45
3	Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. <i>Leukemia</i> , 2020, 34, 1052-1061.	3.3	39
4	Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. <i>British Journal of Haematology</i> , 2020, 191, 433-441.	1.2	52
5	Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. <i>Blood</i> , 2019, 134, 85-89.	0.6	20
6	Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 186, e56-e60.	1.2	9
7	Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. <i>Blood</i> , 2019, 134, 3904-3904.	0.6	4
8	Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. <i>Blood</i> , 2019, 134, 2926-2926.	0.6	5
9	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
10	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
11	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. <i>Leukemia</i> , 2018, 32, 2572-2579.	3.3	66
12	Predictors of Success in Treatment-Free Remission: A Single Centre Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S224.	0.2	0
13	Inflammatory myopathies after allogeneic stem cell transplantation. <i>Muscle and Nerve</i> , 2018, 58, 790-795.	1.0	23
14	Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. <i>Blood</i> , 2018, 132, 948-961.	0.6	152
15	Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. <i>Blood</i> , 2018, 132, 459-459.	0.6	6
16	The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. <i>Blood</i> , 2018, 132, 1731-1731.	0.6	10
17	CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. <i>Blood</i> , 2017, 129, 1166-1176.	0.6	143
18	Comment on "EKB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study". <i>Leukemia Research</i> , 2017, 55, 55-57.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. <i>Blood Advances</i> , 2017, 1, 2193-2205.	2.5	115
20	Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. <i>Frontiers in Immunology</i> , 2017, 8, 469.	2.2	106
21	Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. <i>Blood</i> , 2016, 127, 1017-1023.	0.6	179
22	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2016, 101, 1267-1274.	1.7	22
23	The incidence, mortality and timing of <i>Pneumocystis jiroveci</i> pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 573-580.	1.3	68
24	KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. <i>Blood</i> , 2015, 126, 2720-2723.	0.6	27
25	Sexual health in hematopoietic stem cell transplant recipients. <i>Cancer</i> , 2015, 121, 4124-4131.	2.0	50
26	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 189-196.	1.3	7
27	Secondary solid cancer screening following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1013-1023.	1.3	136
28	Transplant to treatment-free remission: the evolving view of "cure"™ in chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2015, 8, 785-797.	1.0	4
29	Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points. <i>European Journal of Haematology</i> , 2015, 95, 103-112.	1.1	9
30	Monoclonal antibody targeting of IL-3 receptor $\alpha$ with CSL362 effectively depletes CML progenitor and stem cells. <i>Blood</i> , 2014, 123, 1218-1228.	0.6	89
31	KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure. <i>Blood</i> , 2014, 124, 814-814.	0.6	1
32	Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1125-1136.	2.0	20
33	Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. <i>Leukemia Research</i> , 2012, 36, 982-989.	0.4	43
34	Effective Elimination of CML Progenitor and Stem Cells Through Combination of $\alpha$ -CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. <i>Blood</i> , 2012, 120, 32-32.	0.6	1
35	T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. <i>Blood</i> , 2011, 117, 2691-2699.	0.6	77
36	Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. <i>Haematologica</i> , 2011, 96, 432-440.	1.7	114

#	ARTICLE	IF	CITATIONS
37	Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. <i>Leukemia</i> , 2011, 25, 629-637.	3.3	27
38	The impact of gene profiling in chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 181-190.	0.7	27
39	Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. <i>Blood</i> , 2009, 113, 2245-2255.	0.6	113
40	Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. <i>Blood</i> , 2009, 113, 875-882.	0.6	61
41	Allografts Selectively Photodepleted of GvHD Causing T Cells and Followed by Low-Level Immunosuppression: A Novel Method to Improve Disease Control After HLA-Matched Sibling Transplantations.. <i>Blood</i> , 2009, 114, 515-515.	0.6	0
42	Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. <i>Leukemia</i> , 2008, 22, 1721-1727.	3.3	44
43	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. <i>Blood</i> , 2008, 111, 236-242.	0.6	337
44	Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 2163-2166.	0.6	21
45	The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. <i>Blood</i> , 2007, 110, 380-383.	0.6	126
46	High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. <i>Blood</i> , 2007, 110, 770-775.	0.6	32
47	Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. <i>Blood</i> , 2007, 110, 1924-1932.	0.6	158
48	Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. <i>Blood</i> , 2007, 110, 1689-1697.	0.6	69
49	Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1216-1223.	2.0	134
50	Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. <i>Leukemia</i> , 2007, 21, 2145-2152.	3.3	167
51	Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies.. <i>Blood</i> , 2007, 110, 287-287.	0.6	2
52	Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).. <i>Blood</i> , 2007, 110, 464-464.	0.6	0
53	Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. <i>Blood</i> , 2006, 107, 205-212.	0.6	127
54	Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14483-14488.	3.3	109

#	ARTICLE	IF	CITATIONS
55	Selective Depletion of CD25+ Host-Reactive Donor Lymphocytes from Allografts Preserves a CD25 <sup>hi</sup> CD4 <sup>+</sup> foxp3 <sup>+</sup> Fraction of T Cells and Thereby Provides a Source for Efficient Reconstitution of Regulatory T Cells and Additional GVHD Control.. Blood, 2006, 108, 308-308.	0.6	3
56	WT1-Specific CD8+ T Lymphocytes May Participate in the Elimination of Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 3679-3679.	0.6	1
57	Cytotoxic CD8 T Cell Immune Responses to Wilms Tumor Protein (WT-1) Characterizes Immunosuppression-Responsive Myelodysplasia (MDS).. Blood, 2006, 108, 849-849.	0.6	2
58	Cytotoxic T Lymphocyte Responses to PR1 Peptide in Chronic Myeloid Leukemia Patients Inversely Correlate with Proteinase 3 and Elastase Expression but Donor PR1 Responses Determine Survival after Stem Cell Transplantation.. Blood, 2006, 108, 3697-3697.	0.6	0
59	Hematopoietic Stem Cells and Primitive Progenitors Express Leukemia-Associated Antigens That May Be Targets for Graft-Versus-Leukemia Effect or for Vaccine-Based Immunotherapy in Chronic Myeloid Leukemia.. Blood, 2006, 108, 2125-2125.	0.6	1
60	Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia. Cancer Research, 2005, 65, 8912-8919.	0.4	176
61	Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival.. Blood, 2005, 106, 1984-1984.	0.6	0
62	Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. British Journal of Haematology, 2001, 112, 228-236.	1.2	101
63	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. British Journal of Haematology, 2001, 115, 569-574.	1.2	66
64	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2000, 96, 2712-2716.	0.6	243
65	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2000, 96, 2712-2716.	0.6	0
66	Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1999, 23, 827-828.	1.3	32
67	Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. Atherosclerosis, 1995, 116, 241-245.	0.4	14